Latest On Cyclacel Pharmaceuticals, Inc (CYCC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 08:19 EST | News | Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 18:46 EST | News | Cyclacel Pharmaceuticals GAAP EPS of -$0.47 beats by $0.19 | N/A | |
| 2023-05-11 03:52 EST | News | Cyclacel Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-05-03 22:51 EST | News | Cyclacel Pharmaceuticals receives $4.7M R&D tax credit | N/A | |
| 2023-03-07 03:25 EST | News | Cyclacel Pharmaceuticals GAAP EPS of -$0.60 misses by $0.12 | N/A | |
| 2023-03-07 03:25 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-11-09 22:54 EST | News | Cyclacel Pharmaceuticals GAAP EPS of -$0.42 beats by $0.14 | N/A | |
| 2022-11-09 22:54 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-09 04:40 EST | News | Cyclacel Pharmaceuticals Q3 2022 Earnings Preview | N/A | |
| 2022-08-12 01:16 EST | News | Cyclacel stock rises 16% as net loss narrows, income grows | N/A | |
| 2022-08-11 08:21 EST | News | Cyclacel Pharmaceuticals GAAP EPS of -$0.46 beats by $0.08, revenue of $0M | N/A | |
| 2022-08-11 08:21 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-09 22:40 EST | News | Cyclacel Pharmaceuticals Q2 2022 Earnings Preview | N/A | |
| 2022-08-07 22:51 EST | News | Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis | N/A | |
| 2022-05-11 22:03 EST | News | Cyclacel Pharmaceuticals GAAP EPS of -$0.42 beats by $0.27 | N/A | |
| 2022-05-11 22:02 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-11 02:33 EST | News | Cyclacel Pharmaceuticals Q1 2022 Earnings Preview | N/A | |
| 2022-04-12 10:35 EST | News | Cyclacel Pharmaceuticals jumps on preclinical data for blood cancer treatment fadraciclib | N/A | |
| 2022-03-30 00:21 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-28 19:57 EST | News | Cyclacel Pharmaceuticals GAAP EPS of -$1.34 | N/A | |
| 2022-03-25 19:40 EST | News | Cyclacel Pharmaceuticals Q4 2021 Earnings Preview | N/A | |
| 2022-03-21 11:36 EST | News | Cyclacel Pharmaceuticals (CYCC) Investor Presentation - Slideshow | N/A | |
| 2022-01-06 11:14 EST | News | Cyclacel Pharmaceuticals reveals plans for cancer drug programs for 2022 | N/A | |
| 2021-11-11 04:32 EST | News | Cyclacel Pharmaceuticals EPS beats by $0.23 | N/A | |
| 2021-11-11 04:31 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-10 06:11 EST | News | Cyclacel Pharmaceuticals Q3 2021 Earnings Preview | N/A | |
| 2021-11-06 00:11 EST | News | Cyclacel gets dosing underway in phase 1/2 oral fadraciclib study | N/A | |
| 2021-10-05 02:49 EST | News | Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video) | N/A | |
| 2021-08-12 15:35 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-11 19:15 EST | News | Cyclacel Pharmaceuticals EPS misses by $0.07 | N/A | |
| 2021-07-21 03:43 EST | News | Dosing underway in Cyclacel Pharma's Phase 1/2 study of oral fadraciclib in solid tumors and lymphomas | N/A | |
| 2021-04-06 19:28 EST | News | Checking In On Cyclacel Pharmaceuticals | N/A | |
| 2021-03-23 21:56 EST | News | Cyclacel Pharmaceuticals (CYCC) Presents At 33rd Annual Roth Virtual Conference - Slideshow | N/A | |
| 2021-03-12 23:16 EST | News | Cyclacel Pharmaceuticals prices $12.65M underwritten public offering | N/A | |
| 2021-03-12 02:20 EST | News | Cyclacel proposes capital raise through underwritten public offering | N/A | |
| 2021-03-12 02:20 EST | News | Cyclacel Pharmaceuticals readies stock offering | N/A | |
| 2021-03-02 07:31 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-01 07:33 EST | Earnings Estimate | An EPS average of -$4.26 is estimated for the 2022 year. | Sell | |
| 2021-03-01 07:33 EST | Earnings Estimate | An EPS average of -$0.54 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-28 07:29 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-25 23:24 EST | News | Cyclacel Pharmaceuticals EPS misses by $2.21 | N/A | |
| 2021-02-25 23:24 EST | News | Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-01-11 16:41 EST | News | Cyclacel issues key business objectives for 2021 | N/A | |
| 2020-12-22 18:43 EST | News | Cyclacel Pharma inks securities purchase agreement for $7M | N/A | |
| 2020-12-13 03:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 03:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 03:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 21:28 EST | News | Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-12 11:30 EST | Earnings Estimate | An EPS average of -$0.61 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-11 16:53 EST | News | Cyclacel Pharmaceuticals EPS misses by $1.74 | N/A | |
About Cyclacel Pharmaceuticals, Inc (CYCC):
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
General
- Name Cyclacel Pharmaceuticals, Inc
- Symbol CYCC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:20
- Last Split Date2020-04-15
- Fiscal Year EndDecember
- IPO Date2004-05-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.cyclacel.com
View More
Valuation
- Trailing PE 0.27
- Price/Sales (Trailing 12 Mt.) 74.57
- Price/Book (Most Recent Quarter) 1.61
- Enterprise Value Revenue 6.1
- Enterprise Value EBITDA 0.1
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.23
- Next Year EPS Estimate -$2.46
- Next Quarter EPS Estimate -$0.53
- Return on Assets -26%
- Return on Equity -38%
- Revenue 150000
- Earnings Per Share -$0.57
- Revenue Per Share $0.01
- Gross Profit -4759000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 74.83 million
- EBITDA -9438000
- Analyst Target Price $21.33
- Book Value Per Share $5.32
View More
Share Statistics
- Shares Outstanding 9.18 million
- Shares Float 6.22 million
- % Held by Insiders 281%
- % Held by Institutions 22.42%
- Shares Short 1.05 million
- Shares Short Prior Month 1.03 million
- Short Ratio 0.79
- Short % of Float 15%
- Short % of Shares Outstanding 15%
View More
Technicals
- Beta 1.25
- 52 Week High $11.42
- 52 Week Low $3.12
- 50 Day Moving Average 7.82
- 200 Day Moving Average 5.48
View More
Dividends
- Dividend Date 2020-04-15
- ExDividend Date N/A
- Dividend Yield 0%
View More
Cyclacel Pharmaceuticals, Inc (CYCC) Dividend Calendar:
CYCC's last dividend payment was made to shareholders on April 15, 2020.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Cyclacel Pharmaceuticals, Inc (CYCC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $N/A | -$1.34 | -$0.52 | -160.19% |
| 2020-09-30 | 2020-11-11 | $N/A | -$0.47 | -$0.49 | 4.08% |
| 2020-06-30 | 2020-08-12 | $N/A | -$0.58 | -$0.44 | -31.82% |
| 2020-03-31 | 2020-05-12 | $N/A | -$1.48 | -$2.80 | 47.14% |
| 2019-12-31 | 2020-02-26 | $N/A | -$2.80 | -$2.40 | -16.67% |
| 2019-09-30 | 2019-11-13 | $N/A | -$2.20 | -$3.30 | 33.33% |
| 2019-06-30 | 2019-08-13 | $N/A | -$2.20 | -$3.00 | 26.67% |
| 2019-03-31 | 2019-05-14 | $N/A | -$2.80 | -$3.80 | 26.32% |
| 2018-12-31 | 2019-03-27 | $150000 | -$3.40 | -$2.60 | -30.77% |
| 2018-09-30 | 2018-11-12 | $N/A | -$3.60 | -$3.40 | -5.88% |
| 2018-06-30 | 2018-08-09 | $N/A | -$3.20 | -$2.40 | -33.33% |
| 2018-03-31 | 2018-05-14 | $N/A | -$2.40 | -$2.60 | 7.69% |
| 2017-12-31 | 2018-03-28 | $N/A | -$3.48 | -$0.73 | -376.12% |
| 2017-09-30 | 2017-11-02 | $N/A | -$18.13 | ||
| 2017-06-30 | 2017-08-09 | $N/A | -$10.09 | ||
| 2017-03-31 | 2017-05-11 | $N/A | -$7.52 | ||
| 2016-12-31 | 2017-03-28 | $277000 | -$13.80 | -$14.60 | 5.48% |
| 2016-09-30 | 2016-11-14 | $205000 | -$17.20 | -$18.80 | 8.51% |
| 2016-06-30 | 2016-08-10 | $222000 | -$20.10 | ||
| 2016-03-31 | 2016-05-11 | $139000 | -$20.85 | ||
| 2015-12-31 | 2016-03-24 | $424000 | -$24.00 | -$19.20 | -25% |
| 2015-09-30 | 2015-11-12 | $712000 | -$0.96 | -$1.08 | 11.11% |
| 2015-06-30 | 2015-08-11 | $296000 | -$23.71 | ||
| 2015-03-31 | 2015-05-12 | $512000 | -$2.28 | -$3.00 | 24% |
| 2014-12-31 | 2015-03-24 | $247000 | -$2.52 | -$3.12 | 19.23% |
| 2014-09-30 | 2014-11-11 | $735000 | -$2.64 | -$3.12 | 15.38% |
| 2014-06-30 | 2014-08-12 | $356000 | -$52.80 | -$72.00 | 26.67% |
| 2014-03-31 | 2014-05-13 | $396000 | -$60.00 | -$63.20 | 5.06% |
| 2013-12-31 | 2014-03-25 | $299000 | -$45.60 | -$80.00 | 43% |
| 2013-09-30 | 2013-11-12 | $309000 | -$76.80 | -$76.80 | 0% |
| 2013-06-30 | 2013-08-14 | $264000 | $24.00 | -$84.00 | 128.57% |
| 2013-03-31 | 2013-05-14 | $212000 | -$283.62 | ||
| 2012-12-31 | 2013-03-28 | $5000 | -$143.16 | ||
| 2012-09-30 | 2012-11-13 | $38000 | -$58.99 | ||
| 2012-06-30 | 2012-08-14 | $26000 | -$100.80 | -$134.40 | 25% |
| 2012-03-31 | 2012-05-14 | $N/A | -$100.80 | -$134.40 | 25% |
| 2011-12-31 | 2012-03-29 | $699000 | -$117.60 | -$134.40 | 12.5% |
| 2011-09-30 | 2011-11-14 | $N/A | -$117.60 | -$140.00 | 16% |
| 2011-06-30 | 2011-08-11 | $N/A | -$134.40 | -$179.20 | 25% |
| 2011-03-31 | 2011-05-12 | $N/A | -$168.00 | -$142.80 | -17.65% |
| 2010-12-31 | 2011-03-23 | $138000 | -$117.60 | -$168.00 | 30% |
| 2010-09-30 | 2010-11-11 | $159000 | -$184.80 | -$252.00 | 26.67% |
| 2010-06-30 | 2010-08-05 | $119000 | -$302.40 | -$277.20 | -9.09% |
| 2010-03-31 | 2010-05-13 | $270000 | -$302.40 | -$252.00 | -20% |
| 2009-12-31 | 2010-03-23 | $187000 | -$302.40 | -$310.80 | 2.7% |
| 2009-09-30 | 2009-11-03 | $230000 | -$218.40 | -$369.60 | 40.91% |
| 2009-06-30 | 2009-08-06 | $266000 | -$571.20 | -$428.40 | -33.33% |
| 2009-03-31 | 2009-05-14 | $228000 | -$420.00 | -$495.60 | 15.25% |
| 2008-12-31 | 2009-03-31 | $251000 | -$655.20 | -$487.20 | -34.48% |
| 2008-09-30 | 2008-11-06 | $269000 | -$1,444.80 | -$715.68 | -101.88% |
| 2008-06-30 | 2008-08-07 | $180000 | -$705.60 | -$672.00 | -5% |
| 2008-03-31 | 2008-05-09 | $177000 | -$520.80 | -$576.80 | 9.71% |
| 2007-12-31 | 2008-03-11 | $12000 | -$940.80 | -$756.00 | -24.44% |
| 2007-09-30 | 2007-11-07 | $33000 | -$352.80 | -$613.20 | 42.47% |
| 2007-06-30 | 2007-08-09 | $32000 | -$302.40 | -$600.60 | 49.65% |
| 2007-03-31 | 2007-05-10 | $52000 | -$453.60 | -$694.40 | 34.68% |
| 2006-12-31 | 2007-03-15 | $117000 | -$604.80 | -$655.20 | 7.69% |
| 2006-09-30 | 2006-11-13 | $83000 | -$571.20 | -$730.80 | 21.84% |
| 2006-06-30 | 2006-08-14 | $36000 | -$806.40 | -$697.20 | -15.66% |
| 2006-03-31 | 2006-05-16 | $151000 | -$3,040.80 | -$940.80 | -223.21% |
| 2005-12-31 | 2006-03-22 | $N/A | -$3,024.00 | -$3,192.00 | 5.26% |
| 2005-09-30 | 2005-11-14 | $N/A | -$10,752.00 | -$3,864.00 | -178.26% |
| 2005-06-30 | 2005-08-15 | $N/A | -$5,040.00 | -$5,544.00 | 9.09% |
| 2005-03-31 | 2005-05-16 | $N/A | -$6,216.00 | -$6,468.00 | 3.9% |
| 2004-12-31 | 2005-03-31 | $N/A | -$8,400.00 | -$8,064.00 | -4.17% |
| 2004-09-30 | 2004-11-11 | $N/A | -$7,728.00 | -$7,014.00 | -10.18% |
| 2004-06-30 | 2004-08-12 | $N/A | -$6,888.00 | -$6,384.00 | -7.89% |
| 2004-03-31 | 2004-05-13 | $N/A | -$27,048.00 | -$5,460.00 | -395.38% |
Cyclacel Pharmaceuticals, Inc (CYCC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Cyclacel Pharmaceuticals, Inc (CYCC) Chart:
Cyclacel Pharmaceuticals, Inc (CYCC) News:
Below you will find a list of latest news for Cyclacel Pharmaceuticals, Inc (CYCC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cyclacel Pharmaceuticals, Inc (CYCC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.05 | CALL | 3 | 8 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.05 | CALL | 0 | 0 | 310.66 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2032-10-21 | 5 | 0 | CALL | 3 | 0 | FALSE | 0 | 0 |
Latest CYCC Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 3:40 PM EST | 100 | $1.16 |
| Jun 13, 2022 7:01 PM EST | 37 | $1.1 |
| Jun 13, 2022 7:52 PM EST | 1 | $1.12 |
Cyclacel Pharmaceuticals, Inc (CYCC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078132/0001104659-20-078132-index.htm |
| 2019-06-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1130166/000000000019009794/0000000000-19-009794-index.htm |
| 2020-03-16 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1130166/000000000020002333/0000000000-20-002333-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1130166/000103738920000011/0001037389-20-000011-index.htm |
| 2019-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465919058326/0001104659-19-058326-index.htm |
| 2019-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465919063316/0001104659-19-063316-index.htm |
| 2019-12-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465919071119/0001104659-19-071119-index.htm |
| 2019-12-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465919071120/0001104659-19-071120-index.htm |
| 2019-12-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465919071121/0001104659-19-071121-index.htm |
| 2020-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920001633/0001104659-20-001633-index.htm |
| 2020-01-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920003040/0001104659-20-003040-index.htm |
| 2020-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920025388/0001104659-20-025388-index.htm |
| 2020-03-13 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1130166/000110465920033221/0001104659-20-033221-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920035359/0001104659-20-035359-index.htm |
| 2020-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920039601/0001104659-20-039601-index.htm |
| 2020-04-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/0001104659-20-046360-index.htm |
| 2020-04-14 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1130166/000110465920046445/0001104659-20-046445-index.htm |
| 2020-04-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1130166/000110465920047707/0001104659-20-047707-index.htm |
| 2020-04-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920048783/0001104659-20-048783-index.htm |
| 2020-04-22 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1130166/000110465920049790/0001104659-20-049790-index.htm |
| 2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920051033/0001104659-20-051033-index.htm |
| 2020-04-30 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1130166/000110465920054110/0001104659-20-054110-index.htm |
| 2020-05-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920056224/0001104659-20-056224-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920058082/0001104659-20-058082-index.htm |
| 2020-05-12 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1130166/000110465920060149/0001104659-20-060149-index.htm |
| 2020-05-12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1130166/000110465920060162/0001104659-20-060162-index.htm |
| 2020-05-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920060188/0001104659-20-060188-index.htm |
| 2020-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920077996/0001104659-20-077996-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078120/0001104659-20-078120-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078122/0001104659-20-078122-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078123/0001104659-20-078123-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078125/0001104659-20-078125-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078129/0001104659-20-078129-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078131/0001104659-20-078131-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920078132/0001104659-20-078132-index.htm |
| 2020-08-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920093904/0001104659-20-093904-index.htm |
| 2020-08-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920098751/0001104659-20-098751-index.htm |
| 2020-09-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920101897/0001104659-20-101897-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920103472/0001104659-20-103472-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920105223/0001104659-20-105223-index.htm |
| 2020-10-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920118938/0001104659-20-118938-index.htm |
| 2020-10-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000110465920118939/0001104659-20-118939-index.htm |
| 2020-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000110465920119515/0001104659-20-119515-index.htm |
| 2017-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420417047504/0001144204-17-047504-index.htm |
| 2017-11-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420417057718/0001144204-17-057718-index.htm |
| 2017-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000114420417057898/0001144204-17-057898-index.htm |
| 2017-12-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/0001144204-17-063359-index.htm |
| 2018-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418014114/0001144204-18-014114-index.htm |
| 2018-03-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418017544/0001144204-18-017544-index.htm |
| 2018-04-12 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1130166/000114420418020307/0001144204-18-020307-index.htm |
| 2018-04-12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1130166/000114420418020312/0001144204-18-020312-index.htm |
| 2018-04-12 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418020331/0001144204-18-020331-index.htm |
| 2018-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418028187/0001144204-18-028187-index.htm |
| 2018-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000114420418028276/0001144204-18-028276-index.htm |
| 2018-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032151/0001144204-18-032151-index.htm |
| 2018-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032709/0001144204-18-032709-index.htm |
| 2018-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032712/0001144204-18-032712-index.htm |
| 2018-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032714/0001144204-18-032714-index.htm |
| 2018-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032715/0001144204-18-032715-index.htm |
| 2018-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032717/0001144204-18-032717-index.htm |
| 2018-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032718/0001144204-18-032718-index.htm |
| 2018-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418032720/0001144204-18-032720-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418043301/0001144204-18-043301-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000114420418043377/0001144204-18-043377-index.htm |
| 2018-08-17 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1130166/000114420418045356/0001144204-18-045356-index.htm |
| 2018-09-10 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418048727/0001144204-18-048727-index.htm |
| 2018-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420418048729/0001144204-18-048729-index.htm |
| 2018-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418049491/0001144204-18-049491-index.htm |
| 2018-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418052431/0001144204-18-052431-index.htm |
| 2018-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418052510/0001144204-18-052510-index.htm |
| 2018-10-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1130166/000114420418052526/0001144204-18-052526-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418058900/0001144204-18-058900-index.htm |
| 2018-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/0001144204-18-059346-index.htm |
| 2018-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420418065121/0001144204-18-065121-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/0001144204-19-000763-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419000788/0001144204-19-000788-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419000789/0001144204-19-000789-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419000790/0001144204-19-000790-index.htm |
| 2019-01-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419001462/0001144204-19-001462-index.htm |
| 2019-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419013535/0001144204-19-013535-index.htm |
| 2019-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419016316/0001144204-19-016316-index.htm |
| 2019-03-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1130166/000114420419016652/0001144204-19-016652-index.htm |
| 2019-04-10 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1130166/000114420419019102/0001144204-19-019102-index.htm |
| 2019-04-10 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1130166/000114420419019104/0001144204-19-019104-index.htm |
| 2019-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419026002/0001144204-19-026002-index.htm |
| 2019-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000114420419026070/0001144204-19-026070-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029254/0001144204-19-029254-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029255/0001144204-19-029255-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029256/0001144204-19-029256-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029258/0001144204-19-029258-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029259/0001144204-19-029259-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029260/0001144204-19-029260-index.htm |
| 2019-05-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029261/0001144204-19-029261-index.htm |
| 2019-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029472/0001144204-19-029472-index.htm |
| 2019-06-03 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1130166/000114420419029516/0001144204-19-029516-index.htm |
| 2019-06-20 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1130166/000114420419031712/0001144204-19-031712-index.htm |
| 2019-06-20 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1130166/000114420419031713/0001144204-19-031713-index.htm |
| 2019-07-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419034583/0001144204-19-034583-index.htm |
| 2019-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419039535/0001144204-19-039535-index.htm |
| 2019-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000114420419039620/0001144204-19-039620-index.htm |
| 2019-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000114420419044143/0001144204-19-044143-index.htm |
| 2019-09-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1130166/000114420419044917/0001144204-19-044917-index.htm |
| 2019-09-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1130166/000114420419046127/0001144204-19-046127-index.htm |
| 2017-11-22 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1130166/000121465917006929/0001214659-17-006929-index.htm |
| 2018-02-02 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1130166/000139382518000023/0001393825-18-000023-index.htm |
| 2017-07-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000140840817000016/0001408408-17-000016-index.htm |
| 2017-07-27 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1130166/000140840817000019/0001408408-17-000019-index.htm |
| 2017-08-25 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1130166/000140840817000025/0001408408-17-000025-index.htm |
| 2020-05-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1130166/000140840820000020/0001408408-20-000020-index.htm |
| 2020-05-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1130166/000140840820000023/0001408408-20-000023-index.htm |
| 2019-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000155837019010952/0001558370-19-010952-index.htm |
| 2020-03-05 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1130166/000155837020002077/0001558370-20-002077-index.htm |
| 2020-05-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000155837020006443/0001558370-20-006443-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000155837020010569/0001558370-20-010569-index.htm |
| 2017-07-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1130166/000157104917006730/0001571049-17-006730-index.htm |
| 2017-07-19 | S-1MEF | Registration adding securities to prior Form S-1 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1130166/000157104917006795/0001571049-17-006795-index.htm |
| 2017-07-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000157104917006801/0001571049-17-006801-index.htm |
| 2017-07-20 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1130166/000157104917006835/0001571049-17-006835-index.htm |
| 2017-07-21 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1130166/000157104917006854/0001571049-17-006854-index.htm |
| 2017-07-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000157104917006881/0001571049-17-006881-index.htm |
| 2017-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000157104917007255/0001571049-17-007255-index.htm |
| 2017-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1130166/000157104917007326/0001571049-17-007326-index.htm |
| 2017-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1130166/000157104917007382/0001571049-17-007382-index.htm |
| 2018-03-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1130166/000157104918000206/0001571049-18-000206-index.htm |
| 2017-07-18 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1130166/999999999517001937/9999999995-17-001937-index.htm |
| 2019-06-21 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1130166/999999999519001406/9999999995-19-001406-index.htm |
| 2020-04-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1130166/999999999520000791/9999999995-20-000791-index.htm |
| 2018-11-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1130166/999999999718009034/9999999997-18-009034-index.htm |
Cyclacel Pharmaceuticals, Inc (CYCC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cyclacel Pharmaceuticals, Inc (CYCC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 281%Institutional Ownership: 2242%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2017-07-19 | Capital LTD Eastern | 10% Share Holder | Buy | 850,000.00 | 2.00 | 1,700,000.00 | 2,167,261.00 | https://www.sec.gov/Archives/edgar/data/1130166/000140840817000016/0001408408-17-000016-index.htm |